CLINICAL_TRIALS
trial_result
· 2023-06-26
Clinical Trial Update: Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 2]
Summary
Phase 2 trial evaluating REGN3918 for safety and efficacy in paroxysmal nocturnal hemoglobinuria has completed with results posted in 2023.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Regeneron Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Status: COMPLETED | Results posted: 2023-06-26